Expert Insights

Additional risk factors for PV proposed in the literature

Read transcript Close transcript

We also look at different variables. We definitely look at the leukocyte count. I think there is evidence that the higher leukocyte count, maybe the higher the thrombotic event. Platelet count being high could correlate with thrombotic event. Some people look at like, for example, the JAK2 allele burden related homozygotic or heterozygotic because that could have implications many more on disease progression to fibrosis rather than risk of thrombosis. And then we are starting to see people looking at molecular profiling in those patients, looking at other molecular events which are probably more studied in myelofibrosis at this point. We're starting to learn about those as well in P vera but they are not yet established into any risk stratification.

head shot of Dr Komrokji
Rami S Komrokji, MD Clinical Director of the Malignant Hematology Department Moffitt Cancer Center | Tampa, FL
Dr Rami Komrokji is a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center and is a professor in medicine and oncologic sciences at the University of South Florida’s College of Medicine. Dr Komrokji has authored or co-authored more than 80 peer-reviewed manuscripts, 20 book chapters, and more than 200 abstracts on hematologic malignancies and is a peer reviewer for such medical journals as Blood, Journal of Clinical Oncology, and Leukemia. Dr Komrokji serves as a member on the MDS Panel of the National Comprehensive Cancer Network® (NCCN®).